Daily Stock Analysis, IMUC, ImmunoCellular Therapeutics Ltd, priceseries

ImmunoCellular Therapeutics Ltd. Daily Stock Analysis
Stock Information
Open
0.02
Close
0.02
High
0.02
Low
0.02
Previous Close
0.02
Daily Price Gain
0.00
YTD High
0.03
YTD High Date
Jan 28, 2019
YTD Low
0.01
YTD Low Date
Jan 2, 2019
YTD Price Change
0.01
YTD Gain
30.53%
52 Week High
0.29
52 Week High Date
May 9, 2018
52 Week Low
0.01
52 Week Low Date
Jan 2, 2019
52 Week Price Change
-0.24
52 Week Gain
-90.46%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 23. 2017
2.69
Apr 3. 2017
2.84
7 Trading Days
5.67%
Link
LONG
Jun 9. 2017
1.19
Jun 12. 2017
1.31
1 Trading Days
10.50%
Link
LONG
Jul 3. 2017
0.90
Jul 10. 2017
1.21
4 Trading Days
33.89%
Link
Company Information
Stock Symbol
IMUC
Exchange
NYSE MKT
Company URL
http://www.imuc.com
Company Phone
818-264-2300
CEO
Gary S. Titus
Headquarters
California
Business Address
23622 CALABASAS ROAD, SUITE 300, CALABASAS, CA 91302
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000822411
About

ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.

Description

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.